R&D Facts & Figures

There are three Research Centres of Excellence: Braine-l’Alleud (Belgium), Cambridge (UK) and Slough (UK), where UCB’s R&D headquarters are located. These centres focus on CNS, inflammation and oncology/immunology respectively.

The main development sites are in Atlanta (US), Braine-l’Alleud (Belgium), Monheim (Germany), Research Triangle Park (US), Slough (UK) and Tokyo (Japan). Many of these sites also host NCDS (non-clinical developmental sciences) and global regulatory affairs activities.

Other R&D activities are undertaken at key manufacturing sites in Bulle (Switzerland), Rochester (New York, US) and Shannon (Ireland).

More facts

• There are over two thousand employees worldwide in R&D.
• UCB is committed to R&D with an investment of 25% of sales each year.
• Our therapeutic areas of interest are CNS, inflammation and oncology.
• UCB combines novel NCE and NBE science and technology.
• Development pipeline: twelve compounds in development to treat seventeen indications.
• Research pipeline: molecules in CNS, inflammation and oncology indications in discovery research or pre-clinical development.